Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr | Aprea TherapeuticsAPRE | Open-market buy | 01/30 | 02/02 | 5,700 sh | $0.89 | $5,073 | +20.6% |
Oren GiladPresident/CEO | Aprea TherapeuticsAPRE | Open-market buy | 01/30 | 02/02 | 28,100 sh | $0.89 | $25,009 | +8.1% |
John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr | Aprea TherapeuticsAPRE | Open-market buy | 25/12/10 | 25/12/11 | 5,000 sh | $1.17 | $5,850 | +22.0% |
Marc DueyDirector | Aprea TherapeuticsAPRE | Open-market buy | 25/12/10 | 25/12/11 | 21,459 sh | $1.17 | $25,107.03 | +9.1% |
Aprea TherapeuticsAPRE | Open-market buy | 25/04/03 | 25/04/04 | 5,500 sh2 trades | $1.84avg. | $10,110.21 | +1.6% | |
Marc DueyDirector | Aprea TherapeuticsAPRE | Open-market sale | 24/10/18 | 24/10/25 | 6,462 sh | $4.58 | $29,595.96 | −2.7% |
Oren GiladPresident/CEO | Aprea TherapeuticsAPRE | Open-market buy | 24/10/23 | 24/10/24 | 500 sh | $3.92 | $1,960 | +0.2% |
Marc DueyDirector | Aprea TherapeuticsAPRE | Open-market buy | 24/10/16 | 24/10/17 | 30,000 sh | $4.39 | $131,700 | +14.3% |
Oren GiladPresident/CEO | Aprea TherapeuticsAPRE | Open-market buy | 24/10/15 | 24/10/16 | 250 sh | $2.90 | $725 | +0.1% |
Marc DueyDirector | Aprea TherapeuticsAPRE | Open-market buy | 24/10/14 | 24/10/16 | 190 sh | $2.58 | $490.2 | +0.1% |
John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr | Aprea TherapeuticsAPRE | Open-market buy | 24/10/11 | 24/10/16 | 50 sh | $2.46 | $123 | +0.3% |
Aprea TherapeuticsAPRE | Open-market buy | 24/10/10–24/10/14 | 24/10/15 | 1,150 sh2 trades | $2.58avg. | $2,971 | +0.3% | |
Bernd R. SeizingerDirector | Aprea TherapeuticsAPRE | Open-market buy | 24/10/11 | 24/10/15 | 10,000 sh | $2.68 | $26,800 | +28.8% |
John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr | Aprea TherapeuticsAPRE | Open-market buy | 24/10/10 | 24/10/15 | 450 sh | $2.61 | $1,174.5 | +2.4% |
John B. Henneman IIIDirector | Aprea TherapeuticsAPRE | Open-market buy | 24/03/13 | 24/03/14 | 6,860 sh | $7.29 | $50,009.4 | +536.4% |
John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr | Aprea TherapeuticsAPRE | Open-market buy | 24/03/13 | 24/03/14 | 1,010 sh | $7.29 | $7,362.9 | +7.0% |
Bernd R. SeizingerDirector | Aprea TherapeuticsAPRE | Open-market buy | 24/03/13 | 24/03/14 | 6,860 sh | $7.29 | $50,009.4 | +25.6% |
Oren GiladPresident, CEO | Aprea TherapeuticsAPRE | Open-market buy | 24/03/13 | 24/03/14 | 2,000 sh | $7.29 | $14,580 | +0.6% |
Aprea TherapeuticsAPRE | Open-market buy | 23/06/06–23/06/07 | 23/06/08 | 10,097 sh2 trades | $3.66avg. | $36,953.56 | +62.2% |